Inventing the Future of Longevity
NOVOS is a science-first longevity biotechnology company building the world’s most rigorously validated system for supporting healthspan and longevity, starting with aging itself.
THE PROBLEM
The Longevity Problem
Aging is the primary driver of decline in health and function, yet most health solutions focus on managing symptoms rather than addressing the biology that causes aging in the first place.
For decades, supplements and wellness products have relied on isolated ingredients, untested combinations, and theoretical benefits, rarely evaluated as complete systems in rigorous studies.
We believed longevity — and you — deserved a different standard.
THE APPROACH
A Biology-First Approach
NOVOS was founded to do what consumer health had never done: treat aging as a biological process that can be measured, targeted, and improved.
We design formulations and tools based on the fundamental mechanisms of aging, then validate them through mechanistic studies, preclinical research, and human trials. Not as individual ingredients, but as integrated systems.
OUR STANDARDS
- Evidence before claims
- Biology before trends
- Systems before single ingredients
- Long-term health over short-term hype
- Safety, transparency, and scientific rigor always
These standards guide every decision we make, from research to formulation to education.
PROOF
Evidence, Not Assumptions
- Double-blind, placebo-controlled human clinical trials
- Mechanistic studies with leading research institutions
- Animal lifespan and cellular aging research
- Patents on multi-ingredient longevity systems
- Independently tested for purity and safety
- Millions of servings taken across countries, ages, and lifestyles
Our Story
Our founders, driven by personal health journeys and profound scientific expertise, established NOVOS with the determination to address aging at its root.
Chris Mirabile
Founder & CEO:
After surviving a brain tumor, Chris Mirabile began questioning why medicine waits for disease instead of protecting health earlier.
That question led him to collaborate with leading scientists from Harvard, MIT, the Salk Institute, and beyond to build NOVOS: a company dedicated to preserving health before decline begins.
What started as a personal journey became a commitment to helping people extend both longevity and quality of life through better science, better tools, and better standards.
Scientific Leadership
Guided by the World’s Leading Aging Scientists
Dr. George Church, PhD
Dr. J. Pedro Magalhães, PhD
Real People. Real Impact.
Behind every data point is a human story. Countless people across the world now use NOVOS as part of their daily health routine, to feel better today while investing in long-term health.
Evidence, Not Assumptions
Yes, we have scientific evidence.
3 Powerful Formulas. 20 Innovative Ingredients. 500+ Studies. View our growing record of direct and indirect NOVOS studies.
In a recent study of aged mice, NOVOS Core increased lifespan by 18%, surpassing all previously studied supplements in similar research, including NAD+ boosters like nicotinamide riboside.
In just 6 months, 73% of NOVOS Core and NOVOS Boost users experienced a significant reduction in their biological aging pace, with an average slowdown of 8.7% which works out to be 31.75 days younger per year. Nobody’s aging sped up.
Ingredients in NOVOS Core reduced the size of human senescent cells (cells that age and become toxic) by approximately 50% in an in-vitro study, offering effects comparable to a pharmaceutical longevity drug, rapamycin*.
After 6 months, all participants experienced increased skin firmness by an average of 22%, enhancing both appearance and feel.
NOVOS Core users ranked (#2, #5, and #7) for lowest rates of aging in a global competition that uses the DunedinPACE algorithm created by Duke and Columbia scientists to measure epigenetic changes.
Ingredients in NOVOS Core were able to prevent DNA damage by up to 77% in skin cells exposed to irradiation (e.g., UV rays) in an in-vitro study. In another human skin cell study, DNA was protected from moderate and high intensity chemo drugs.
NOVOS Core’s ingredients reduced unwanted cell death processes called oxytosis/ferroptosis, by 50%, while also reducing cellular inflammation, in an in-vitro human cellular study.
In a recent study of aged mice, NOVOS Core increased lifespan by 18%, surpassing all previously studied supplements in similar research, including NAD+ boosters like nicotinamide riboside.
In just 6 months, 73% of NOVOS Core and NOVOS Boost users experienced a significant reduction in their biological aging pace, with an average slowdown of 8.7% which works out to be 31.75 days younger per year. Nobody’s aging sped up.
Ingredients in NOVOS Core reduced the size of human senescent cells (cells that age and become toxic) by approximately 50% in an in-vitro study, offering effects comparable to a pharmaceutical longevity drug, rapamycin*.
After 6 months, all participants experienced increased skin firmness by an average of 22%, enhancing both appearance and feel.
NOVOS Core users ranked (#2, #5, and #7) for lowest rates of aging in a global competition that uses the DunedinPACE algorithm created by Duke and Columbia scientists to measure epigenetic changes.
Ingredients in NOVOS Core were able to prevent DNA damage by up to 77% in skin cells exposed to irradiation (e.g., UV rays) in an in-vitro study. In another human skin cell study, DNA was protected from moderate and high intensity chemo drugs.
NOVOS Core’s ingredients reduced unwanted cell death processes called oxytosis/ferroptosis, by 50%, while also reducing cellular inflammation, in an in-vitro human cellular study.
NOVOS, established in 2018, is a pioneer in longevity, reshaping the future of aging and enabling healthier, longer lives.
2018
NOVOS is founded. Vision established: target aging biology, not symptoms.
2019
First formulations designed with scientific advisors. Early human testing begins.
2020
Expanded testing, brand launch, and educational platform created.
2021
NOVOS Core and Boost launch to early adopters. First in vitro aging studies completed and show reduced DNA damage.
2022
NOVOS Age biological age test launches. Studies show reduced cellular senescence.
2023
Case studies show slowed biological aging. Peer-reviewed in vitro study shows reduced DNA damage from chemotherapeutics.
2024
NOVOS Core demonstrates ~20% lifespan extension in aged mice, and in vitro study shows reduced ferroptosis and cellular inflammation. NOVOS Vital is launched.
2025
Launch of the world’s first longevity bar. NOVOS enters Mayo Clinic retail.
2026
Completion of double-blind, placebo-controlled human clinical trial validating NOVOS Core as a complete system.
A Commitment Beyond Commerce
NOVOS is a Public Benefit Corporation, legally committed to balancing profit with purpose: advancing human health, longevity research, and public education alongside commercial success.
We donate a portion of profits and equity to nonprofits advancing longevity research, including the Lifespan Research Institute (LRI), and support initiatives like the Dog Aging Project — helping dogs live longer, healthier lives while accelerating insights into human aging.
Longevity should benefit everyone.
Building What Comes Next
We believe the future of medicine begins before disease, and we’re building it now.
Subscribe for exclusive insights and updates directly from the forefront of longevity science. Get the most from NOVOS with tailored advice and special promotions.
Exclusive Content
First look at breakthroughs and innovations.
Tailored Tips
Personalized health insights.
Special Offers
Subscribers-only discounts and promotions.
